Stock BNGO BIONANO GENOMICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Bionano Genomics, Inc.

Equities

BNGO

US09075F3055

Real-time Estimate Cboe BZX
Other stock markets
 10:03:18 29/04/2024 pm IST 		5-day change 1st Jan Change
0.836 USD +6.35% Intraday chart for Bionano Genomics, Inc. +10.08% -55.70%
17/04 Bionano Genomics, Hangzhou Diagens Biotechnology to Commercialize Cytogenetic Workflow for Reproductive Health MT
17/04 Bionano Genomics, Inc. and Hangzhou Diagens Biotechnology Co., Ltd. Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis That Combines OGM and Artificial Intelligence CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Scotiabank Trims Price Target on Bionano Genomics to $6 From $7, Maintains Sector Outperform Rating
MT
Maxim Group Adjusts Bionano Genomics Price Target to $6 From $30, Maintains Buy Rating
MT
EF Hutton Initiates Bionano Genomics at Buy With $1.75 Price Target
MT
BTIG Adjusts Price Target on Bionano Genomics to $2 From $3, Maintains Buy Rating
MT
Oppenheimer Adjusts Bionano Genomics' Price Target to $9 From $12, Maintains Outperform Rating
MT
Scotiabank Initiates Bionano Genomics at Sector Outperform With $4 Price Target
MT
BTIG Assumes Bionano Genomics at Buy With $3.50 Price Target
MT
Oppenheimer Adjusts Bionano Genomics Price Target to $12 From $14, Maintains Outperform Rating
MT
BTIG Adjusts Bionano Genomics' Price Target to $7 From $10, Reiterates Buy Rating
MT
Maxim Group Adjusts Bionano Genomics Price Target to $6 From $12, Maintains Buy Rating
MT
BIONANO GENOMICS : BTIG Starts Bionano Genomics at Buy With $10 Price Target
MT
BIONANO GENOMICS : Oppenheimer Adjusts Bionano Genomics PT to $14 From $15, Maintains Outperform Rating
MT
BIONANO GENOMICS : Oppenheimer Adjusts Bionano Genomics' PT to $15 From $1.50, Citing Balance Sheet Expansion, Potential of $100 Genome; Outperform Rating Kept
MT
BIONANO GENOMICS : Roth Capital Downgrades Bionano Genomics to Neutral From Buy; Price Target is $0.75
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BNGO Stock
  4. News Bionano Genomics, Inc.
  5. Analyst Reco.